639 related articles for article (PubMed ID: 34473462)
1. Antineutrophil cytoplasmic antibody (ANCA) vasculitis: pathophysiology, diagnosis, and the evolving treatment landscape.
Koening CL; von Hennigs I
Am J Manag Care; 2021 Sep; 27(15 Suppl):S267-S276. PubMed ID: 34473462
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
3. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.
Berti A; Warner R; Johnson K; Cornec D; Schroeder DR; Kabat BF; Langford CA; Kallenberg CGM; Seo P; Spiera RF; St Clair EW; Fervenza FC; Stone JH; Monach PA; Specks U; Merkel PA;
J Autoimmun; 2019 Dec; 105():102302. PubMed ID: 31320177
[TBL] [Abstract][Full Text] [Related]
4. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
[TBL] [Abstract][Full Text] [Related]
5. Avacopan for the Treatment of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis.
Alihosseini C; Kopelman H; Zaino M; Feldman SR
Ann Pharmacother; 2023 Dec; 57(12):1449-1454. PubMed ID: 36975183
[TBL] [Abstract][Full Text] [Related]
6. The management of anti-neutrophil cytoplasmic antibody-associated vasculitis: what has changed in the last 10 years?
Suresh E
Br J Hosp Med (Lond); 2022 Feb; 83(2):1-10. PubMed ID: 35243884
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
[TBL] [Abstract][Full Text] [Related]
8. How the Availability of Anti-C5a Agents Could Change the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Roccatello D; Fenoglio R; Oddone V; Sciascia S
Kidney Blood Press Res; 2022; 47(8):506-513. PubMed ID: 35665698
[TBL] [Abstract][Full Text] [Related]
9. Updates in ANCA-associated vasculitis.
Ross C; Makhzoum JP; Pagnoux C
Eur J Rheumatol; 2022 Jul; 9(3):153-166. PubMed ID: 35156630
[TBL] [Abstract][Full Text] [Related]
10. Novel Therapies for ANCA-associated Vasculitis.
Monti S; Brandolino F; Milanesi A; Xoxi B; Delvino P; Montecucco C
Curr Rheumatol Rep; 2021 Apr; 23(6):38. PubMed ID: 33909172
[TBL] [Abstract][Full Text] [Related]
11. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.
Jayne DRW; Bruchfeld AN; Harper L; Schaier M; Venning MC; Hamilton P; Burst V; Grundmann F; Jadoul M; Szombati I; Tesař V; Segelmark M; Potarca A; Schall TJ; Bekker P;
J Am Soc Nephrol; 2017 Sep; 28(9):2756-2767. PubMed ID: 28400446
[TBL] [Abstract][Full Text] [Related]
12. ANCA-associated vasculitis: diagnostic and therapeutic strategy.
Ozaki S
Allergol Int; 2007 Jun; 56(2):87-96. PubMed ID: 17460438
[TBL] [Abstract][Full Text] [Related]
13. Avacopan for the Treatment of ANCA-Associated Vasculitis.
Jayne DRW; Merkel PA; Schall TJ; Bekker P;
N Engl J Med; 2021 Feb; 384(7):599-609. PubMed ID: 33596356
[TBL] [Abstract][Full Text] [Related]
14. Renal improvement and remission in a patient with refractory ANCA-associated vasculitis treated with avacopan.
Alvarez L; Kambham N; Su R
J Nephrol; 2023 Nov; 36(8):2365-2370. PubMed ID: 37036661
[TBL] [Abstract][Full Text] [Related]
15. Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Wallace ZS; Fu X; Liao K; Kallenberg CGM; Langford CA; Merkel PA; Monach P; Seo P; Specks U; Spiera R; St Clair EW; Zhang Y; Choi H; Stone JH
Arthritis Rheumatol; 2019 Nov; 71(11):1879-1887. PubMed ID: 31162829
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
[TBL] [Abstract][Full Text] [Related]
17. Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis.
Thompson GE; Fussner LA; Hummel AM; Schroeder DR; Silva F; Snyder MR; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; St Clair EW; Stone JH; Specks U
Front Immunol; 2020; 11():2053. PubMed ID: 33013868
[No Abstract] [Full Text] [Related]
18. Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.
Fussner LA; Hummel AM; Schroeder DR; Silva F; Cartin-Ceba R; Snyder MR; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; William St Clair E; Tchao NK; Stone JH; Specks U;
Arthritis Rheumatol; 2016 Jul; 68(7):1700-10. PubMed ID: 26882078
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial.
Merkel PA; Jayne DR; Wang C; Hillson J; Bekker P
JMIR Res Protoc; 2020 Apr; 9(4):e16664. PubMed ID: 32088663
[TBL] [Abstract][Full Text] [Related]
20. The evolving treatment of ANCA-associated vasculitides.
Sauranen J; Salmela A; Kahlos K; Antonen J; Ekstrand A; Pettersson T
Duodecim; 2016; 132(16):1449-55. PubMed ID: 29188932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
